CClinicalTrials.gg
WithdrawnNCT02082756Updated Nov 14, 2018

Effects of Berberine Hydrochloride and Bifidobacterium in Prediabetes Prevention and Treatment

A Phase 2/3 interventional study of Bifidobacterium viable pharmaceutics and Berberine Hydrochloride in Prediabetes, sponsored by Xijing Hospital. Withdrawn at 4 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-11-14.

Sponsored by Xijing Hospital · Phase 2/3, Interventional, and Prevention

Why this study was withdrawn
The sponsor have not enough money to support this trial
Phase
Phase 2/3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The aim of this study is to assess the beneficial effects of Bifidobacterium and Berberine Hydrochloride on lowering glucose and delaying progress to diabetes in patients with prediabetes and to detect the potential mechanism.

Read the detailed description

Gut microbiota may play an important role in patients with prediabetes. Berberine, which is usually used as an antibiotic drug, has been reported a potential glucose-lowering effect in vitro and in vivo studies. Bifidobacterium, as a familiar probiotics, can modulate gut microbiota and improve glucose and lipid metabolism in animal experiments. Therefore, the aim of this study is to assess the beneficial effects of Bifidobacterium and Berberine Hydrochloride on lowering glucose and delaying progress to diabetes in patients with prediabetes and to detect the potential mechanism.

02

Conditions studied

  • Prediabetes

Keywords

  • Prediabetes
  • Berberine Hydrochloride
  • Bifidobacterium
03

In context

Prediabetic State

999 studies on the registry are indexed under Prediabetic State; 238 are open to participants now.

Browse Prediabetic State studies →

Lead sponsor

Xijing Hospital is the lead sponsor of 465 studies on the registry; 157 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Informed consent obtained before any trial-related activities
  • Male or female between 18 and 70 years of age
  • 19≤Body mass index(BMI)≤30kg/m2
  • No participate in any clinical trial at least 3 months
  • Fasting blood glucose(FBG)\<7.0mmol/L and 2-hour postprandial blood glucose(2hPBG)\<11.1mmol/L
  • Females in child-bearing period should be given birth control
  • No severe disease about heart, lung and kidney
  • Ability and willingness to adhere to the protocol including performance of self-monitored blood glucose (SMBG) profiles according to the protocol;
  • Subject is likely to comply with the Investigators instruction.

Exclusion criteria

Exclusion Criteria:

  • Type 2 diabetes mellitus or type 1 diabetes mellitus
  • Females of childbearing potential who are pregnant,breastfeeding or intend to become pregnant or are not using adequate contraceptive methods
  • Impaired liver function, defined as Aspartate aminotransferase(AST) or Alanine transaminase(ALT)> 2 times upper limit of normal (central laboratory)
  • Impaired renal function, defined as serum-creatinine≥133μmol/L
  • Uncontrolled treated/untreated severe hypertension (systolic blood pressure≥160mmHg and /or diastolic blood pressure≥95mmHg)
  • Chronic gastrointestinal diseases
  • Cancer and medical history of cancer (except basal cell skin cancer or squamous cell skin cancer)
  • Any clinically significant disease or disorder, which in the Investigator's opinion could interfere with the results of the trial
  • Mental incapacity, psychiatric disorder, unwillingness or language barriers precluding adequate understanding or co-operation, including subjects not able to read and write
  • Previous participation in this trial. Participation is defined as randomized. Re-screening of screening failures is allowed only once within the limits of the recruitment period
  • Known or suspected hypersensitivity to trial products or related products
  • Known or suspected abuse of alcohol, narcotics or illicit drugs.
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Bifidobacterium viable pharmaceutics

    Bifidobacterium viable pharmaceutics, 2 Capsules, 2/day, 12 weeks

    Drug: Bifidobacterium viable pharmaceutics

  • Experimental
    Berberine Hydrochloride

    Berberine Hydrochloride, 0.5g, 2/day, 12 weeks

    Drug: Berberine Hydrochloride

  • No intervention
    lifestyle counseling

Interventions

  • DrugBifidobacterium viable pharmaceutics
  • DrugBerberine Hydrochloride
06

What researchers measure

Primary outcomes

  1. Change in 2-hour postprandial blood glucose between baseline to week 12

    2-hour postprandial blood glucose are measured at baseline and week 12 during a 2 hour-meal test.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Gut microbiome composition

    Faecal bacterial composition determined from microbiological cultures and deep metagenomic next-generation sequencing of bacterial DNA in feces.

    Time frame: Baseline and week 12

  2. Adverse effects

    Standardized questionaries regarding gastrointestinal function are filled out at each study visit (0, 4, 8 and 12 weeks after randomization) to detect possible adverse effects of antibiotics. In addition, subjects are given a calendar and informed to write down any symptom or illness during the study period.

    Time frame: From baseline to week 12

07

Study locations

4 sites
  • First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an,, Shaanxi 710061, China
  • Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710004, China
  • The 323rd Hospital of People's Liberation Army
    Xi'an, Shaanxi 710054, China
  • Shaanxi Provincial People's Hospital
    Xi'an, Shaanxi 710068, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02082756
Lead sponsor
Xijing Hospital
Responsible party
Sponsor
First posted
Mar 10, 2014
Start date
Nov 2015 (estimated)
Primary completion
Apr 2018 (estimated)
Completion
Apr 2018 (estimated)
Last update
Nov 14, 2018

Study contacts

Qiu Ji, Ph.D..M.D.
principal investigator · Department of Endocrinology, Xijing Hospital, Fourth Military Medical University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion